organization · Reporting owner
General Atlantic (CIN), L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CinCor Pharma, Inc.CINC · Entity 116342 | 10% owner | August 11, 2022 | August 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CinCor Pharma, Inc.
Report date August 11, 2022 · Filed August 15, 2022
Jointly reported with GENERAL ATLANTIC GENPAR (BERMUDA), L.P., GAP (Bermuda) L.P., GAP Coinvestments CDA, L.P., General Atlantic (SPV) GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnote | 4,209,470 |
Reported balance
After 2022-08-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-11 · Purchase · Acquired 83,000 · Balance 4,209,470 F4: The shares of Common Stock were purchased by GA CIN in a registered offering which closed on August 10, 2022, at a price of $30.00. F1: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V"). F2: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda. F3: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V").
F2: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda.
F3: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.
F4: The shares of Common Stock were purchased by GA CIN in a registered offering which closed on August 10, 2022, at a price of $30.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2022 Filed Aug 15, 2022 18:22 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | PurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | 83,000 | $30.00 | $2,490,000.00 |
DisclosureSEC source: 0000950142-22-002526 · es220278538_4-cincor2.xml · nonDerivative · entry 1 GENERAL ATLANTIC GENPAR (BERMUDA), L.P. · CIK 0001467927 · 10% owner GAP (Bermuda) L.P. · CIK 0001406817 · 10% owner GAP Coinvestments CDA, L.P. · CIK 0001356474 · 10% owner General Atlantic (CIN), L.P. · CIK 0001891495 · 10% owner General Atlantic (SPV) GP, LLC · CIK 0001793940 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,209,470 F4 · kind: The shares of Common Stock were purchased by GA CIN in a registered offering which closed on August 10, 2022, at a price of $30.00. F1 · ownership.nature: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V"). F2 · ownership.nature: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda. F3 · ownership.nature: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 02:32 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | ConversionSeries B Preferred Stock · Derivative | 8,250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-22-000344 · es220217248_4-cincor2.xml · derivative · entry 3 GENERAL ATLANTIC GENPAR (BERMUDA), L.P. · CIK 0001467927 · 10% owner GAP (Bermuda) L.P. · CIK 0001406817 · 10% owner GAP Coinvestments CDA, L.P. · CIK 0001356474 · 10% owner General Atlantic (CIN), L.P. · CIK 0001891495 · 10% owner General Atlantic (SPV) GP, LLC · CIK 0001793940 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 2,426,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F1 · price: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F1 · derivative.exercise_date: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F1 · derivative.expiration_date: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F2 · ownership.nature: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V"). F3 · ownership.nature: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda. F4 · ownership.nature: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 02:32 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | PurchaseCommon Stock | 1,700,000 | $16.00 | $27,200,000.00 |
DisclosureSEC source: 0000950142-22-000344 · es220217248_4-cincor2.xml · nonDerivative · entry 2 GENERAL ATLANTIC GENPAR (BERMUDA), L.P. · CIK 0001467927 · 10% owner GAP (Bermuda) L.P. · CIK 0001406817 · 10% owner GAP Coinvestments CDA, L.P. · CIK 0001356474 · 10% owner General Atlantic (CIN), L.P. · CIK 0001891495 · 10% owner General Atlantic (SPV) GP, LLC · CIK 0001793940 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,126,470 F5 · kind: The shares of Common Stock were purchased by GA CIN in the Issuer's IPO which closed on January 11, 2022, at a price of $16.00. F2 · ownership.nature: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V"). F3 · ownership.nature: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda. F4 · ownership.nature: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 02:32 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | ConversionCommon Stock, par value $0.00001 per share ("Common Stock") | 2,426,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-22-000344 · es220217248_4-cincor2.xml · nonDerivative · entry 1 GENERAL ATLANTIC GENPAR (BERMUDA), L.P. · CIK 0001467927 · 10% owner GAP (Bermuda) L.P. · CIK 0001406817 · 10% owner GAP Coinvestments CDA, L.P. · CIK 0001356474 · 10% owner General Atlantic (CIN), L.P. · CIK 0001891495 · 10% owner General Atlantic (SPV) GP, LLC · CIK 0001793940 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,426,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F1 · price: Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022. F2 · ownership.nature: Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V"). F3 · ownership.nature: The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda. F4 · ownership.nature: The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.